JP2020073561A5 - - Google Patents

Download PDF

Info

Publication number
JP2020073561A5
JP2020073561A5 JP2020001139A JP2020001139A JP2020073561A5 JP 2020073561 A5 JP2020073561 A5 JP 2020073561A5 JP 2020001139 A JP2020001139 A JP 2020001139A JP 2020001139 A JP2020001139 A JP 2020001139A JP 2020073561 A5 JP2020073561 A5 JP 2020073561A5
Authority
JP
Japan
Prior art keywords
amino
oxo
dihydro
phenoxyphenyl
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020001139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020073561A (ja
JP6985433B2 (ja
Filing date
Publication date
Priority claimed from JP2017562758A external-priority patent/JP6646072B2/ja
Application filed filed Critical
Publication of JP2020073561A publication Critical patent/JP2020073561A/ja
Publication of JP2020073561A5 publication Critical patent/JP2020073561A5/ja
Application granted granted Critical
Publication of JP6985433B2 publication Critical patent/JP6985433B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020001139A 2015-06-03 2020-01-08 チロシンキナーゼ阻害剤 Active JP6985433B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562170547P 2015-06-03 2015-06-03
US62/170,547 2015-06-03
US201562271689P 2015-12-28 2015-12-28
US62/271,689 2015-12-28
JP2017562758A JP6646072B2 (ja) 2015-06-03 2016-06-02 チロシンキナーゼ阻害剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017562758A Division JP6646072B2 (ja) 2015-06-03 2016-06-02 チロシンキナーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2020073561A JP2020073561A (ja) 2020-05-14
JP2020073561A5 true JP2020073561A5 (enExample) 2020-07-09
JP6985433B2 JP6985433B2 (ja) 2021-12-22

Family

ID=56118090

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017562758A Active JP6646072B2 (ja) 2015-06-03 2016-06-02 チロシンキナーゼ阻害剤
JP2020001139A Active JP6985433B2 (ja) 2015-06-03 2020-01-08 チロシンキナーゼ阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017562758A Active JP6646072B2 (ja) 2015-06-03 2016-06-02 チロシンキナーゼ阻害剤

Country Status (33)

Country Link
US (5) US20180162861A1 (enExample)
EP (3) EP3303334B1 (enExample)
JP (2) JP6646072B2 (enExample)
KR (3) KR102666352B1 (enExample)
CN (2) CN113149983B (enExample)
AU (2) AU2016270973B2 (enExample)
CA (1) CA2987335A1 (enExample)
CL (2) CL2017003073A1 (enExample)
CO (1) CO2017012947A2 (enExample)
CR (1) CR20170593A (enExample)
DK (1) DK3303334T3 (enExample)
DO (1) DOP2017000279A (enExample)
EA (1) EA039006B1 (enExample)
ES (1) ES2878030T3 (enExample)
HK (1) HK1252378A1 (enExample)
HR (1) HRP20211249T1 (enExample)
HU (1) HUE055419T2 (enExample)
IL (2) IL255946A (enExample)
LT (1) LT3303334T (enExample)
MX (2) MX383213B (enExample)
MY (1) MY190548A (enExample)
PE (1) PE20180521A1 (enExample)
PH (2) PH12021551681A1 (enExample)
PL (1) PL3303334T3 (enExample)
PT (1) PT3303334T (enExample)
RS (1) RS62290B1 (enExample)
SG (1) SG10201912443XA (enExample)
SI (1) SI3303334T1 (enExample)
TN (1) TN2017000501A1 (enExample)
TW (2) TWI810582B (enExample)
UA (1) UA124090C2 (enExample)
WO (1) WO2016196840A1 (enExample)
ZA (2) ZA201708667B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2819741B1 (en) 2012-02-27 2018-03-28 O-Ray Pharma, Inc. Solid drug implants for intracochlear delivery of therapeutics for the treatment of otic disorders
US9266895B2 (en) 2012-09-10 2016-02-23 Principia Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
EP3075681B1 (en) 2013-11-29 2021-06-02 Daizo Corporation Content-accommodating container, content-accommodating product using same, discharging product, and discharging device
EP4681737A3 (en) 2014-02-21 2026-03-11 Principia Biopharma Inc. Salts and solid form of a btk inhibitor
US10485797B2 (en) 2014-12-18 2019-11-26 Principia Biopharma Inc. Treatment of pemphigus
EP3303334B1 (en) * 2015-06-03 2021-06-02 Principia Biopharma Inc. Tyrosine kinase inhibitors
TW201718572A (zh) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
WO2017066014A1 (en) 2015-10-14 2017-04-20 Sunnylife Pharma Inc. Bruton's tyrosine kinase inhibitors
IL293621B2 (en) 2016-06-29 2023-09-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile
EP3487857B1 (en) * 2016-07-25 2021-09-01 Nerviano Medical Sciences S.r.l. Purine and 3-deazapurine analogues as choline kinase inhibitors
WO2018156901A1 (en) * 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
EP3789040A4 (en) * 2018-04-27 2022-03-09 ONO Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
CA3224985C (en) 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
PL3808747T3 (pl) * 2018-09-13 2025-03-17 Kissei Pharmaceutical Co., Ltd. Związek imidazopirydynonowy
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
JP7795454B2 (ja) 2019-10-14 2026-01-07 プリンシピア バイオファーマ インコーポレイテッド （ｒ）－２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルを投与することにより免疫性血小板減少症を治療する方法
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN113045484B (zh) * 2019-12-27 2024-01-26 南京药石科技股份有限公司 一种2-氨基-2-(1-甲基-4-哌啶基)丙烷-1-醇的制备方法
CN113149891B (zh) * 2020-01-07 2024-02-02 南京药石科技股份有限公司 一种2-氨基-2-（1-甲基-4-哌啶基）乙醇的制备方法
KR20220130179A (ko) 2020-01-20 2022-09-26 젠자임 코포레이션 재발성 다발성 경화증(rms)에 대한 치료용 티로신 키나제 저해제
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021209884A1 (en) 2020-01-22 2022-09-15 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
JP2023520021A (ja) * 2020-03-30 2023-05-15 アイジーアイエー ファーマシューティカルズ インコーポレイテッド チロシンキナーゼ阻害剤の小児用製剤
WO2022033460A1 (zh) * 2020-08-10 2022-02-17 江苏恒瑞医药股份有限公司 Btk抑制剂治疗疾病的用途
CN116157404B (zh) 2020-08-14 2025-10-14 诺华股份有限公司 杂芳基取代的螺哌啶基衍生物及其药物用途
EP4237423B1 (en) 2020-11-02 2024-12-11 Boehringer Ingelheim International GmbH Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors
CN118434732A (zh) 2020-12-10 2024-08-02 建新公司 Tolebrutinib的晶型及其制备方法和用途
WO2022140511A1 (en) * 2020-12-23 2022-06-30 Genzyme Corporation 4-amino-3-(4-phenoxyphenyl)-1,3- dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof
CN116710452A (zh) * 2020-12-23 2023-09-05 建新公司 4-氨基-3-(4-苯氧基苯基)-1,3-二氢-2h-咪唑并[4,5-c]吡啶-2-酮衍生物及其盐类
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2022218430A1 (zh) * 2021-04-16 2022-10-20 南京明德新药研发有限公司 咪唑并吡啶类化合物及其应用
WO2022223027A1 (zh) * 2021-04-23 2022-10-27 杭州领业医药科技有限公司 Tolebrutinib晶型、无定型及其制备方法和用途
WO2022242740A1 (zh) * 2021-05-21 2022-11-24 杭州领业医药科技有限公司 Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途
JP2024521412A (ja) * 2021-06-11 2024-05-31 ジェンザイム・コーポレーション トレブルチニブの結晶形並びにその製造方法及び使用
WO2023280132A1 (zh) * 2021-07-06 2023-01-12 苏州晶云药物科技股份有限公司 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法
JP2024533724A (ja) * 2021-09-24 2024-09-12 ドナルドソン，チャドウィック 粘膜を通して薬剤を送達するための乾燥粉末発泡性製剤
TW202334146A (zh) 2021-12-21 2023-09-01 美商健臻公司 （ｒ）－１－（１－丙烯醯基哌啶－３－基）－４－胺基－３－（４－苯氧基苯基）－１ｈ－咪唑並［４，５－ｃ］吡啶－２（３ｈ）－酮及其衍生物的晶型
WO2023172663A1 (en) * 2022-03-09 2023-09-14 Teva Pharmaceuticals International Gmbh Solid state forms of tolebrutinib and of tolebrutinib salts
US20230399313A1 (en) * 2022-06-10 2023-12-14 Advenchen Pharmaceuticals, LLC Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers
AU2023294689A1 (en) * 2022-06-14 2025-01-30 Principia Biopharma Inc. Methods of making tolebrutinib
JP2025521510A (ja) * 2022-06-22 2025-07-10 プリンシピア バイオファーマ インコーポレイテッド 改変されたｂｔｋ阻害剤の作製方法
MA71327A (fr) 2022-06-30 2025-04-30 Principia Biopharma Inc. Inhibiteurs thérapeutiques de tyrosine kinase pour le traitement de la sclérose en plaques et de la myasthénie gravis
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
CN120435291A (zh) 2022-10-11 2025-08-05 普林斯匹亚生物制药公司 用于多发性硬化的治疗性酪氨酸激酶抑制剂
WO2024099242A1 (zh) * 2022-11-07 2024-05-16 天津征程医药科技有限公司 氘代的氨基吡啶衍生物以及包含该化合物的药物组合物
EP4637726A1 (en) 2022-12-20 2025-10-29 Principia Biopharma Inc. Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4- phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one
JP2026505764A (ja) 2023-02-01 2026-02-18 プリンシピア バイオファーマ インコーポレイテッド 多発性硬化症を診断及び治療する方法
WO2025188862A1 (en) 2024-03-06 2025-09-12 Principia Biopharma Inc. Methods of making tolebrutinib
WO2026050513A1 (en) 2024-08-30 2026-03-05 Principia Biopharma Inc. Tolebrutinib for multiple sclerosis

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP1451173A4 (en) 2001-11-01 2005-10-26 Icagen Inc PIPERIDINE
US20060045822A1 (en) 2004-09-01 2006-03-02 Board Of Regents, The University Of Texas System Plasma polymerization for encapsulating particles
CN101056877B (zh) * 2004-09-14 2010-06-09 诺华疫苗和诊断公司 咪唑并喹啉化合物
EP1846405A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
EP2029597A4 (en) 2006-05-31 2011-11-23 Univ California purine analogs
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
PL2526933T3 (pl) * 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
MX2012013622A (es) * 2010-05-31 2013-02-01 Ono Pharmaceutical Co Derivado de purinona.
EA025496B1 (ru) * 2011-05-17 2016-12-30 Принсипиа Биофарма Инк. Ингибиторы тирозинкиназы
MX2013013331A (es) * 2011-05-17 2014-10-17 Principia Biopharma Inc Derivados de azaindol como inhibidores de tirosina-cinasas.
HUE048834T2 (hu) * 2011-05-17 2020-08-28 Univ California Kináz inhibitorok
DK2786996T3 (en) * 2011-11-29 2016-12-19 Ono Pharmaceutical Co Hydrochloride PURINONDERIVAT
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
DK2861599T3 (da) * 2012-06-18 2020-03-02 Principia Biopharma Inc Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
US9266895B2 (en) * 2012-09-10 2016-02-23 Principia Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors
US20140142099A1 (en) * 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP3303334B1 (en) * 2015-06-03 2021-06-02 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN105753863B (zh) 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
WO2017066014A1 (en) 2015-10-14 2017-04-20 Sunnylife Pharma Inc. Bruton's tyrosine kinase inhibitors

Similar Documents

Publication Publication Date Title
JP6776399B2 (ja) ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用
JP2025508703A5 (enExample)
JP6586098B2 (ja) キナーゼ阻害剤としてのピラゾリル尿素
US7642263B2 (en) Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
JP6218260B2 (ja) Ｊａｋ阻害剤としてのアミノピリミジニル化合物
US20100160286A1 (en) Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
JP2019504821A5 (enExample)
JP2009541268A5 (enExample)
CN114269432A (zh) 作为p2x3抑制剂的氨基喹唑啉衍生物
JP2015500862A5 (enExample)
US20110053910A1 (en) 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
US20090253676A1 (en) Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes
CA2677572A1 (en) 3-amino-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives as pkc inhibitors
JP2010513283A (ja) 新規なオキサジアゾール化合物
TW201725202A (zh) 新穎經取代吲唑、其製法、包含其之醫藥製劑及其製備藥劑之用途
CN101553224A (zh) 新型咪唑并噻唑和咪唑并唑
CN107257686A (zh) 天疱疮的治疗
HUE026041T2 (en) Pyrrolo-triazinone derivatives as P13K inhibitors
JP2009513575A5 (enExample)
US7655652B2 (en) Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation
JP2015527401A5 (enExample)
CN103288833A (zh) 作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶
RU2014152257A (ru) Гетероциклильные пиримидиновые аналоги в качестве ингибиторов tyk2
JP2022521380A5 (enExample)
JP6983945B2 (ja) 自己免疫性疾患の処置